

# OIE Reference Laboratory Reports Activities

## *Activities in 2021*

**This report has been submitted : 2022-01-29 10:54:37**

<b>Name of disease (or topic) for which you are a designated OIE Reference Laboratory:</b>	Koi herpesvirus disease
<b>Address of laboratory:</b>	Barrack Road, The Nothe, Weymouth, Dorset DT4 8UB UNITED KINGDOM
<b>Tel.:</b>	+44-1305 20.66.42
<b>Fax:</b>	+44-1305 20.66.01
<b>E-mail address:</b>	david.stone@cefas.co.uk
<b>Website:</b>	
<b>Name (including Title) of Head of Laboratory (Responsible Official):</b>	Dr Rachel Hartnell
<b>Name (including Title and Position) of OIE Reference Expert:</b>	David Stone
<b>Which of the following defines your laboratory? Check all that apply:</b>	Governmental

**ToR 1: To use, promote and disseminate diagnostic methods validated according to OIE Standards**

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in OIE Manual (Yes/No)	Total number of test performed last year	
		Nationally	Internationally
Indirect diagnostic tests		Nationally	Internationally
ELISA	YES	0	0
Direct diagnostic tests		Nationally	Internationally
PCR (Bercovier TK)	Yes	0	0
CyHV pol PCR	No	146	10
qPCR Gilad	Yes	27	0
Culture (KF cells)	Yes	14	0

**ToR 2: To develop reference material in accordance with OIE requirements, and implement and promote the application of OIE Standards.  
To store and distribute to national laboratories biological reference products and any other reagents used in the diagnosis and control of the designated pathogens or disease.**

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by the OIE?

No

3. Did your laboratory supply standard reference reagents (non OIE-approved) and/or other diagnostic reagents to OIE Member Countries?

No

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to OIE Member Countries?

No

***ToR 3: To develop, standardise and validate, according to OIE Standards, new procedures for diagnosis and control of the designated pathogens or diseases***

6. Did your laboratory develop new diagnostic methods validated according to OIE Standards for the designated pathogen or disease?

No

7. Did your laboratory develop new vaccines according to OIE Standards for the designated pathogen or disease?

No

***ToR 4: To provide diagnostic testing facilities, and, where appropriate, scientific and technical advice on disease control measures to OIE Member Countries***

8. Did your laboratory carry out diagnostic testing for other OIE Member Countries?

Yes

Name of OIE Member Country seeking assistance	Date (month)	No. samples received for provision of diagnostic support	No. samples received for provision of confirmatory diagnoses
SOUTH AFRICA	January	20	0

9. Did your laboratory provide expert advice in technical consultancies on the request of an OIE Member Country?

No

***ToR 5: To carry out and/or coordinate scientific and technical studies in collaboration with other laboratories, centres or organisations***

10. Did your laboratory participate in international scientific studies in collaboration with OIE Member Countries other than the own?

No

**ToR 6: To collect, process, analyse, publish and disseminate epizootiological data relevant to the designated pathogens or diseases**

11. Did your Laboratory collect epizootiological data relevant to international disease control?

Yes

If the answer is yes, please provide details of the data collected:
Investigated all mortality events, screening for broad range of cyprinid herpes viruses and carp edema virus (CEV). No requests for no confirmation of KHV disease were received during 2021

12. Did your laboratory disseminate epizootiological data that had been processed and analysed?

Yes

If the answer is yes, please provide details of the data collected:
National data submitted to the EURL for the annual report

**13. What method of dissemination of information is most often used by your laboratory?  
(Indicate in the appropriate box the number by category)**

a) Articles published in peer-reviewed journals: 1

I Cano, J Worswick, B Mulhearn, D Stone, G Wood, J Savage, R Paley (2021) A Seasonal Study of Koi Herpesvirus and Koi Sleepy Disease Outbreaks in the United Kingdom in 2018 Using a Pond-Side Test. *Animals* 11 (2), 459

b) International conferences: 1

Cano et al., (2021). Skin mucosal parameters during Koi herpesvirus shedding in common carp, *Cyprinus carpio*. EAFP conference, September 2021, Aberdeen (virtual).

c) National conferences: 0

d) Other:

(Provide website address or link to appropriate information) 0

**ToR 7: To provide scientific and technical training for personnel from OIE Member Countries**

**To recommend the prescribed and alternative tests or vaccines as OIE Standards**

14. Did your laboratory provide scientific and technical training to laboratory personnel from other OIE Member Countries?

No

**ToR 8: To maintain a system of quality assurance, biosafety and biosecurity relevant for the pathogen and the disease concerned**

15. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)
ISO17025	Quality ISO 17025 certificate 2293.pdf

16. Is your quality management system accredited?

Yes

Test for which your laboratory is accredited	Accreditation body
Direct detection of KHV by PCR & confirmation by sequencing	UKAS

17. Does your laboratory maintain a "biorisk management system" for the pathogen and the disease concerned?

Yes

*(See Manual of Diagnostic Tests and Vaccines for Terrestrial Animals, Chapter 1.1.4)*

**ToR 9: To organise and participate in scientific meetings on behalf of the OIE**

18. Did your laboratory organise scientific meetings on behalf of the OIE?

No

19. Did your laboratory participate in scientific meetings on behalf of the OIE?

No

**ToR 10: To establish and maintain a network with other OIE Reference Laboratories designated for the same pathogen or disease and organise regular inter-laboratory proficiency testing to ensure comparability of results**

20. Did your laboratory exchange information with other OIE Reference Laboratories designated for the same pathogen or disease?

No

21. Was your laboratory involved in maintaining a network with OIE Reference Laboratories designated for the same pathogen or disease by organising or participating in proficiency tests?

No

22. Did your laboratory collaborate with other OIE Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

No

**ToR 11: To organise inter-laboratory proficiency testing with laboratories other than OIE Reference Laboratories for the same pathogens and diseases to ensure equivalence of results**

23. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than OIE Reference Laboratories for the same disease?

Yes

Note: See Interlaboratory test comparisons in: Laboratory Proficiency Testing at: <http://www.oie.int/en/our-scientific-expertise/reference-laboratories/proficiency-testing> see point 1.3

Purpose for inter-laboratory test comparisons <sup>1</sup>	No. participating laboratories	Region(s) of participating OIE Member Countries
EURL for fish diseases - Interlaboratory Proficiency Test 2021	45	<input type="checkbox"/> Africa <input type="checkbox"/> Americas <input type="checkbox"/> Asia and Pacific <input checked="" type="checkbox"/> Europe <input type="checkbox"/> Middle East
VetQas PT Scheme on Koi Herpes Virus PCR	15	<input type="checkbox"/> Africa <input type="checkbox"/> Americas <input type="checkbox"/> Asia and Pacific <input type="checkbox"/> Europe <input type="checkbox"/> Middle East

**ToR 12: To place expert consultants at the disposal of the OIE**

24. Did your laboratory place expert consultants at the disposal of the OIE?

Yes

---

Kind of consultancy	Location	Subject (facultative)
Evaluation of diagnostic tests for ad hoc working group	Remote	Participation comparative study of the Tilapia lake virus (TiLV) diagnostic assays

25. Additional comments regarding your report: